ReviewThe Lancet. Oncology2009
Development of therapeutic HPV vaccines.
Review in The Lancet. Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia.American journal of obstetrics and gynecology · 2012Trial
- Review
- Whole-protein screening and multi-modal profiling of antigen-specific CD4Nature communications · 2026Article
- Recent advances in human papillomavirus vaccines and therapeutic strategies: Combating cervical and non-cervical cancers.Genes & diseases · 2026Review
- HPV persistence and CIN2 + Detection in women with normal cytology and Non-16/18 High-Risk HPV positivity.BMC women's health · 2026Article
- Generation of a spontaneous murine HPV + oral cancer model with site-specific oncogene insertion using CRISPR-SONIC.Cell & bioscience · 2025Article
- New Therapeutic Horizons for Advanced or Metastatic Penile Cancer.The Urologic clinics of North America · 2024Review
- Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment.Medical oncology (Northwood, London, England) · 2023Review
- Immunotherapy in Anal Cancer.Current oncology (Toronto, Ont.) · 2023Review
- Lower dietary mineral intake is significantly associated with cervical cancer risk in a population-based cross-sectional study.Journal of Cancer · 2021Article
- Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Robust anti-tumor T cell response with efficient intratumoral infiltration by nanodisc cancer immunotherapy.Advanced therapeutics · 2020Article
- TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer.Journal of immunology research · 2020Article
- Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations.Frontiers in immunology · 2020Review
- Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPVCancer immunology research · 2020Article
- Immunotherapy for HPV associated cancer.Papillomavirus research (Amsterdam, Netherlands) · 2019Review
- Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.Frontiers in immunology · 2018Review
- A therapeutic vaccine targeting HPV E6/E7 with intrinsic Toll-like receptor 2 agonist activity induces antitumor immunity.American journal of cancer research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
At least 15% of human malignant diseases are attributable to the consequences of persistent viral or bacterial infection. Chronic infection with oncogenic human papillomavirus (HPV) types is a necessary, but insufficient, cause in the development of more cancers than any other virus. Currently available prophylactic vaccines have no therapeutic effect for established infection or for disease. Early disease is characterised by tissue sequestration. However, because a proportion of intraepithelial HPV-associated disease undergoes immune-mediated regression, the development of immunotherapeutic strategies is an opportunity to determine proof-of-principle for therapeutic vaccines. In this Review, we discuss recent progress in this field and priorities for future clinical investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.